~7 spots leftby Apr 2026

Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)

Recruiting in Palo Alto (17 mi)
JH
Overseen byJay H Traverse, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Waitlist Available
Sponsor: Minneapolis Heart Institute Foundation
No Placebo Group

Trial Summary

What is the purpose of this trial?

This study will evaluate change in heart muscle function from baseline to three months and twelve months in participants who present with a heart attack and a completely occluded coronary artery. These subjects will be randomized to receive standard Percutaneous transluminal coronary angioplasty (PTCA)/Stenting to open the artery or routine PTCA/Stenting plus post conditioning. Post conditioning commences immediately upon reperfusion using four cycles of thirty second inflations with a standard angioplasty balloon followed by a thirty seconds of reperfusion. The investigators hypothesize that Postconditioning reduces the size of the heart attack when utilized with successful primary Angioplasty/stent.

Research Team

JH

Jay H Traverse, MD

Principal Investigator

Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital

Eligibility Criteria

Inclusion Criteria

Age > 18 years old, < 80 years old
Able to give informed consent
Able to undergo cMRl (cardiac magnetic resonance imaging
See 4 more

Treatment Details

Interventions

  • Post Conditioning + Primary PCI (Procedure)
  • Standard Primary PCI (Procedure)
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Post conditioning + PCIExperimental Treatment1 Intervention
Group II: Standard PCIActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Minneapolis Heart Institute Foundation

Lead Sponsor

Trials
32
Recruited
15,700+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+
Dr. Gary H. Gibbons profile image

Dr. Gary H. Gibbons

National Heart, Lung, and Blood Institute (NHLBI)

Chief Executive Officer since 2012

MD from Harvard Medical School

Dr. James P. Kiley profile image

Dr. James P. Kiley

National Heart, Lung, and Blood Institute (NHLBI)

Chief Medical Officer since 2011

MD from University of California, San Francisco